1
|
Girard C, Chabrillat T, Kerros S, Fravalo P, Thibodeau A. Essential oils mix effect on chicks ileal and caecal microbiota modulation: a metagenomics sequencing approach. Front Vet Sci 2024; 11:1350151. [PMID: 38638639 PMCID: PMC11025455 DOI: 10.3389/fvets.2024.1350151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2023] [Accepted: 02/27/2024] [Indexed: 04/20/2024] Open
Abstract
Introduction Microbiota plays a pivotal role in promoting the health and wellbeing of poultry. Essential oils (EOs) serve as an alternative solution for modulating poultry microbiota. This study aimed to investigate, using amplicon sequencing, the effect of a complex and well-defined combination of EOs feed supplement on both ileal and caecal broiler microbiota, within the context of Salmonella and Campylobacter intestinal colonization. Material and methods For this experiment, 150-day-old Ross chicks were randomly allocated to two groups: T+ (feed supplementation with EO mix 500 g/t) and T- (non-supplemented). At day 7, 30 birds from each group were orally inoculated with 106 CFU/bird of a Salmonella enteritidis and transferred to the second room, forming the following groups: TS+ (30 challenged birds receiving infeed EO mix at 500g/t) and TS- (30 challenged birds receiving a non-supplemented control feed). At day 14, the remaining birds in the first room were orally inoculated with 103 CFU/bird of two strains of Campylobacter jejuni, resulting in the formation of groups T+C+ and T-C+. Birds were sacrificed at day 7, D10, D14, D17, and D21. Ileal and caecal microbiota samples were analyzed using Illumina MiSeq sequencing. At D7 and D14, ileal alpha diversity was higher for treated birds (p <0.05). Results and discussion No significant differences between groups were observed in caecal alpha diversity (p>0.05). The ileal beta diversity exhibited differences between groups at D7 (p < 0.008), D10 (p = 0.029), D14 (p = 0.001) and D17 (p = 0.018), but not at D21 (p = 0.54). For all time points, the analysis indicated that 6 biomarkers were negatively impacted, while 10 biomarkers were positively impacted. Sellimonas and Weissella returned the lowest (negative) and highest (positive) coefficient, respectively. At each time point, treatments influenced caecal microbiota beta diversity (p < 0.001); 31 genera were associated with T+: 10 Ruminoccocaceae genera were alternatively more abundant and less abundant from D7, 7 Lachnospiraceae genera were alternatively more and less abundant from D10, 6 Oscillospiraceae genera were variable depending on the date and 4 Enterobacteriaceae differed from D7. During all the experiment, Campylobacter decreased in treated birds (p < 0.05). This study showed that EO mix modulates ileal and caecal microbiota composition both before and during challenge conditions, increasing alpha diversity, especially in ileum during the early stages of chick life.
Collapse
Affiliation(s)
| | | | | | - Philippe Fravalo
- Faculty of Veterinary Medicine, Research Chair in Meat-Safety (CRSV), Université de Montréal, Saint-Hyacinthe, QC, Canada
- Faculty of Veterinary Medicine, Swine and Avian Infectious Disease Research Centre (CRIPA), Université de Montréal, Saint-Hyacinthe, QC, Canada
- Faculty of Veterinary Medicine, Groupe de recherche et d'enseignement en salubrité alimentaire (GRESA), Université de Montréal, Saint-Hyacinthe, QC, Canada
| | - Alexandre Thibodeau
- Faculty of Veterinary Medicine, Research Chair in Meat-Safety (CRSV), Université de Montréal, Saint-Hyacinthe, QC, Canada
- Faculty of Veterinary Medicine, Swine and Avian Infectious Disease Research Centre (CRIPA), Université de Montréal, Saint-Hyacinthe, QC, Canada
- Faculty of Veterinary Medicine, Groupe de recherche et d'enseignement en salubrité alimentaire (GRESA), Université de Montréal, Saint-Hyacinthe, QC, Canada
| |
Collapse
|
2
|
Merino N, Berdejo D, Pagán E, Girard C, Kerros S, Spinozzi E, Pagán R, García-Gonzalo D. Phenotypic and Genotypic Comparison of Antimicrobial-Resistant Variants of Escherichia coli and Salmonella Typhimurium Isolated from Evolution Assays with Antibiotics or Commercial Products Based on Essential Oils. Pharmaceuticals (Basel) 2023; 16:1443. [PMID: 37895914 PMCID: PMC10610042 DOI: 10.3390/ph16101443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Revised: 10/06/2023] [Accepted: 10/07/2023] [Indexed: 10/29/2023] Open
Abstract
On account of the widespread development and propagation of antimicrobial-resistant (AMR) bacteria, essential oils (EOs) have emerged as potential alternatives to antibiotics. However, as already observed for antibiotics, recent studies have raised concerns regarding the potential emergence of resistant variants (RVs) to EOs. In this study, we assessed the emergence of RVs in Escherichia coli and Salmonella enterica Typhimurium after evolution assays under extended exposure to subinhibitory doses of two commercial EOs (AEN and COLIFIT) as well as to two antibiotics (amoxicillin and colistin). Phenotypic characterization of RVs from evolution assays with commercial EOs yielded no relevant increases in the minimum inhibitory concentration (MIC) of E. coli and did not even modify MIC values in S. Typhimurium. Conversely, RVs of E. coli and S. Typhimurium isolated from evolution assays with antibiotics showed increased resistance. Genotypic analysis demonstrated that resistance to commercial EOs was associated with enhanced protection against oxidative stress and redirection of cell energy toward efflux activity, while resistance to antibiotics was primarily linked to modifications in the cell binding sites of antibiotics. These findings suggest that AEN and COLIFIT could serve as safe alternatives to antibiotics in combating the emergence and dissemination of antimicrobial resistance within the agrifood system.
Collapse
Affiliation(s)
- Natalia Merino
- Departamento de Producción Animal y Ciencia de los Alimentos, Facultad de Veterinaria, Instituto Agroalimentario de Aragón-IA2 (Universidad de Zaragoza-CITA), 50013 Zaragoza, Spain
| | - Daniel Berdejo
- Departamento de Producción Animal y Ciencia de los Alimentos, Facultad de Veterinaria, Instituto Agroalimentario de Aragón-IA2 (Universidad de Zaragoza-CITA), 50013 Zaragoza, Spain
| | - Elisa Pagán
- Departamento de Producción Animal y Ciencia de los Alimentos, Facultad de Veterinaria, Instituto Agroalimentario de Aragón-IA2 (Universidad de Zaragoza-CITA), 50013 Zaragoza, Spain
| | | | | | - Eleonora Spinozzi
- Chemistry Interdiscplinary Project (ChIP), School of Pharmacy, University of Camerino, 62032 Camerino, Italy
| | - Rafael Pagán
- Departamento de Producción Animal y Ciencia de los Alimentos, Facultad de Veterinaria, Instituto Agroalimentario de Aragón-IA2 (Universidad de Zaragoza-CITA), 50013 Zaragoza, Spain
| | - Diego García-Gonzalo
- Departamento de Producción Animal y Ciencia de los Alimentos, Facultad de Veterinaria, Instituto Agroalimentario de Aragón-IA2 (Universidad de Zaragoza-CITA), 50013 Zaragoza, Spain
| |
Collapse
|
3
|
Girard C, Ackhar S, Sassine S, Chapuy L, Jantchou P, Deslandres C. A203 EARLY PROACTIVE DRUG MONITORING STRATEGY OF INFLIXIMAB AS MONOTHERAPY FOR INFLAMMATORY BOWEL DISEASE IN PAEDIATRIC PATIENTS IS ASSOCIATED WITH GOOD SUSTAINED CLINICAL REMISSION. J Can Assoc Gastroenterol 2023. [PMCID: PMC9991299 DOI: 10.1093/jcag/gwac036.203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/09/2023] Open
Abstract
Abstract
Background
Monotherapy with Infliximab (IFX) can be as efficient as combotherapy with immunomodulators in the treatment and maintenance of remission for children with inflammatory bowel disease (IBD) if an early proactive therapeutic drug monitoring strategy is adequately performed. This strategy may allow optimization of blood levels of IFX in order to obtain a sustained clinical response.
Purpose
This study demonstrated that with appropriate early trough levels of IFX before dose #3 and dose #4 , monotherapy was very efficient in inducing remssion at week 52 .
Method
A retrospective study was conducted at CHU Sainte-Justine, Montréal,Canada .Children with IBD 2 to 18 years old diagnosed between 01/2018 and 06/2020 and treated with IFX less than 30 days after diagnosis were included .IFX blood levels were collected before the 3rd and/or 4th dose of IFX and regularly thereafter. Adjustments were done in IFX dose per infusion according to blood levels and clinical response. The primary outcome was clinical remission at one year after diagnosis.The secondary outcomes included: (1) At 52 weeks, the median (IQR) dose of IFX (mg/kg) and the intervals between IFX infusions ; (2) the median (IQR) number of IFX dose changes and the median (IQR) number of blood trough levels of IFX done.
Result(s)
101 patients were included : 56.4% males; 81CD; 18 UC; 2 IBDU. Mean age at diagnosis was 13.2 years (IQR = 11.20 to 15. 20).
Median time to IFX initiation after diagnosis was 5 days (IQR :3-14).Median IFX dose #1: was 8.4 mg/kg (IQR = 5. 8 to 10).
90% of patient had an IFX optimisation (increasing dose and/or shortening intervals) after dose 3 or dose 4. At week 52, 36,5% of patients were receiving IFX infusion every 4 weeks and 30,6% every 6 weeks. The median IFX dose per infusion was 8,9mg/kg (IQR = 7.4- 9,8 ). The IFX doses at week 52 varied greatly according to age at diagnosis The median number of IFX blood level dosage was 4 per patient over a year (IQR=3-5).At week 52, 83 patients (84.6%) achieved clinical remission with a median IFX level of 10.96 (7.05-15.59). 74 /83 (89%) were on monotherapy and 9/83(10.8%) on combotherapy
Image
Conclusion(s)
Early treatment for IBD with IFX as monotherapy and an early proactive optimization strategy is associated with a good sustained steroid free clinical remissionAt week 52, 83 patients (84.6%) achieved clinical remission with a median IFX level of 10.96 (7.05-15.59). 74 /83 (89%) were on monotherapy and 9/83(10.8%) on combotherapy.The majority of the patients required IFX optimization during their first year of treatment. We therefore recommend to proactively monitor blood levels of IFX before the third and fourth dose of IFX and thereafter, in order to lower the risk of treatment failure and anti-infliximab antibodies occurrence.
Please acknowledge all funding agencies by checking the applicable boxes below
None
Disclosure of Interest
C. Girard: None Declared, S. Ackhar: None Declared, S. Sassine: None Declared, L. Chapuy: None Declared, P. Jantchou: None Declared, C. Deslandres Speakers bureau of: moderator and speaker Abbvie and Janssen
Collapse
Affiliation(s)
- C Girard
- Paediatric Gastroenterology , CHU Sainte-Justine
| | - S Ackhar
- Faculté de Médecine , Université de Montréal
| | - S Sassine
- Faculté de Médecine , Université de Montréal
| | - L Chapuy
- Paediatric Gastroenterology , Montreal Children's Hospital , Montreal , Canada
| | - P Jantchou
- Paediatric Gastroenterology , CHU Sainte-Justine
| | - C Deslandres
- Paediatric Gastroenterology , CHU Sainte-Justine
| |
Collapse
|
4
|
Girard C, El-Akri M, Durand M, Guérin O, Rambaud C, Cornu J, Brierre T, Cousin T, Gaillard V, Tricard T, Dupuis H, Hermieu N, Bertrand-Leon P, Chevallier D, Bruyere F, Biardeau X, Hermieu J, Lecoanet P, Capon G, Game X, Saussine C, Peyronnet B, Bentellis I. Efficacy, safety and reoperation-free survival of artificial urinary sphincter in non neurological male patients over 75 years of age. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00819-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
5
|
Redman E, Arguel M, Girard C, Fierville M, Leroy S, Barbry P, Zaragosi L. Exploring IL13 effects on the remodeling of airway epithelial cell populations by single-cell RNA sequencing. Rev Mal Respir 2023. [DOI: 10.1016/j.rmr.2022.11.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
|
6
|
Amoura Z, Jousse Joulin S, Mathian A, Bonnotte B, Girard C, Le Guern V, Thabut G, Todea R, Vidal B, Lahouegue A, Suau D, Fabry-Vendrand C, Chasset F. Premières données d’utilisation d’anifrolumab en France chez les patients atteints d’un lupus érythémateux systémique. Rev Med Interne 2022. [DOI: 10.1016/j.revmed.2022.10.067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
7
|
Parodis I, Gomez A, Tsoi A, Weng Chow J, Pezzella D, Girard C, Stamm T, Boström C. POS1506-HPR SYSTEMATIC LITERATURE REVIEW TO INFORM THE EULAR TASK FORCE FOR RECOMMENDATIONS/POINTS TO CONSIDER FOR THE NON-PHARMACOLOGICAL MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS AND SYSTEMIC SCLEROSIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundThe heterogeneity and complexity of the chronic autoimmune diseases systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) necessitate comprehensive person-centred management, including non-pharmacological approaches. Recommendations for non-pharmacological management are currently lacking.ObjectivesTo perform a systematic literature review to inform the EULAR task force for recommendations/points to consider for the non-pharmacological management of adult patients with SLE and SSc. Among research questions formulated by the task force, we aimed at identifying (i) non-pharmacological interventions that have been evaluated and (ii) their target health domains or organ systems.MethodsWe searched the Medline, Embase, Web of Science Core Collection and CINAHL for articles published between January 2000 and June 2021. From the initial search (n=15,803), 2 researchers independently performed the article selection. Conflicts were discussed until consensus with 2 additional researchers. Subsequent data extraction from the selected articles was performed by 4 researchers, with an overarching guidance by 2 additional researchers. Risk of bias assessment was performed according to Joanna Briggs Institute Critical Appraisal Checklists.ResultsA total of 111 articles for SLE and 75 for SSc were selected for analysis.Non-pharmacological interventions identified for SLE included physical exercise (n=34), psychological support (n=21), dietary therapy and nutrition (n=15), patient education and self-management (n=14), photoprotection (n=5), medication adherence interventions (n=5), complementary and alternative medicine (CAM) e.g., Chinese medicine (n=5), multidisciplinary care (n=4), and phototherapy/laser modalities (n=4).Interventions identified for SSc included physical exercise e.g., hand, oral and general exercise (n=21), phototherapy/laser modalities or shockwave therapy (n=15), patient education and self-management (n=10), CAM (n=8), hand-bathing e.g., in paraffin (n=5), manual therapy e.g., osteopathic manipulative treatment (n=5), dietary therapy and nutrition (n=5), oral hygiene (n=2), hyperbaric oxygen or ozone therapy (n=2) and multidisciplinary care (n=2).Target health domains and organ systems identified within SLE included (in descending order) (i) disease activity, (ii) health-related quality of life (HRQoL), (iii) depression/anxiety, (iv) fatigue, (v) organ damage, (vi) inflammatory markers, (vii) psychological stress, (viii) pain, (ix) body composition/anthropometry, and (x) aerobic capacity.Intervention targets in SSc included (i) functional impairment e.g., hand mobility, (ii) skin sclerosis including microstomia, (iii) HRQoL, (iv) pain, (v) circulation e.g., Raynaud’s phenomena and telangiectasias, (vi) skin ulcers, (vii) oral hygiene, (viii) fatigue, (ix) digestion, and (x) depression/anxiety.ConclusionPhysical exercise was a frequently researched non-pharmacological intervention within both SLE and SSc. While psychological support and dietary therapy/nutrition were frequently investigated in SLE, phototherapy modalities were common in SSc. Patient education and self-management was advocated in both SLE and SSc literature. HRQoL was a frequent target domain in both diseases; while disease activity and psychosocial domains emerged as important targets in SLE, functional impairment and skin-related aspects constituted predominant targets in SSc. Efficacy of interventions varied considerably across studies. Current evidence is limited by the overall small study populations, and the lack of large RCTs.Table 1.Studies categorised by design.Study designSLESScMeta-analysis of RCTs51RCT (including long-term follow-up or post-hoc analysis)4128Non-randomised longitudinal controlled/cohort studies287Retrospective cohort study, cross-sectional or case-control study162Case series or open pilot studies2137AcknowledgementsThe authors would like to thank the members of the EULAR task force for recommendations/points to consider for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis (in alphabetical order by family name) i.e., Helene Alexanderson, Laurent Arnaud, Oliver Distler, Andrea Domján, Els van den Ende, Kim Fligelstone, Agnes Kocher, Maddalena Larosa, Martin Lau, Alexandros Mitropoulos, Mwidimi Ndosi, Gunilla von Perner, Janet Poole, Anthony Redmond, Valentin Ritschl, Yvonne Sjöberg, Tillmann Uhlig, Cecília Varjú, Joke Vriezekolk, Elisabet Welin, and Rene Westhovens, for their contribution to the formulation of the research questions together with IP, CG, TS and CB.Disclosure of InterestsNone declared
Collapse
|
8
|
Assan F, Husson B, Hegazy S, Seneschal J, Aubin F, Mahé E, Jullien D, Sbidian E, D'Incan M, Conrad C, Brenaut E, Girard C, Richard MA, Bachelez H, Viguier M. Palmoplantar pustulosis and acrodermatitis continua of Hallopeau: demographical and clinical comparative study in a large multicentre cohort. J Eur Acad Dermatol Venereol 2022; 36:1578-1583. [PMID: 35366356 PMCID: PMC9546063 DOI: 10.1111/jdv.18127] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2021] [Accepted: 03/23/2022] [Indexed: 12/04/2022]
Abstract
Background Acral pustular disease within the pustular psoriasis/psoriasis‐like spectrum mainly includes palmoplantar pustulosis (PPP) and acrodermatitis continua of Hallopeau (ACH). Scarce data argue for a distinction between these two entities, but no study has compared the clinical and epidemiologic characteristics of ACH and PPP. Objectives We aimed to perform a comparative description of the epidemiological and clinical characteristics of PPP and ACH in a multicentre retrospective cohort. Methods In this multicentre national retrospective cohort study, we compared the epidemiological characteristics, comorbidities and psoriasis characteristics of patients with PPP and ACH. Results A total of 234 patients were included: 203 (87%) with PPP, 18 (8%) with ACH and 13 (6%) with both, according to 2017 ERASPEN criteria. As compared with ACH, PPP was associated with female sex, smoking activity and higher median BMI (P = 0.01, P = 0.02 and P = 0.05 respectively). A family background of psoriasis was more frequent in PPP than ACH. Age of onset of palmoplantar disease was similar between PPP and ACH patients, median age 44 and 48 years respectively. Peripheral joint inflammatory involvement was the only rheumatic disease associated with ACH. The association with another psoriasis type was similar in PPP and ACH (57.6% and 61.1% respectively). Conclusion Our study confirms in a large PPP cohort the predominance of females and a high prevalence of smoking and elevated body mass index but also shows an association of these features in PPP as compared with ACH. In addition, it highlights peripheral arthritis as the only arthritis endotype associated with ACH. Increased knowledge of the immunogenetic backgrounds underlying these two entities is warranted to better stratify pustular psoriasis or psoriasis‐like entities for precision medicine.
Collapse
Affiliation(s)
- F Assan
- Dermatology Department, Hôpital Robert-Debré, Reims, France
| | - B Husson
- Dermatology Department, Hôpital Robert-Debré, Reims, France
| | - S Hegazy
- Dermatology Department, Hôpital Larrey, Toulouse, France
| | - J Seneschal
- Dermatology Department, National Reference Center for Rare Skin Diseases, Hôpital Saint-André, Bordeaux, France
| | - F Aubin
- Dermatology Department and Inserm 1098, Centre Hospitalo-Universitaire (CHU), Besançon, France
| | - E Mahé
- Dermatology Department, Centre Hospitalier (CH), Argenteuil, France
| | - D Jullien
- Clinical Immunology Department, CH Lyon-Sud, Lyon, France
| | - E Sbidian
- Dermatology Department, Hôpital Henri-Mondor, Créteil, France
| | - M D'Incan
- Dermatology Department, CHU Estaing, Clermont-Ferrand, France
| | - C Conrad
- Dermatology Department, Lausanne University Hospital, CHUV, Lausanne, Switzerland
| | - E Brenaut
- Dermatology Department, CHU, Brest, France
| | - C Girard
- Dermatology Department, CHU Lapeyronie, Montpellier, France
| | - M A Richard
- Dermatology Department, CEReSS-EA 3279, Research Center in Health Services and Quality of Life Aix Marseille University, University Hospital Timone, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - H Bachelez
- Université de Paris, Paris, France.,Dermatology Department, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France.,Laboratory of Genetics of Skin Diseases, INSERM UMR1163, Institut Imagine, Necker Hospital, Paris, France
| | - M Viguier
- Dermatology Department, Hôpital Robert-Debré, Reims, France
| | | |
Collapse
|
9
|
Campana F, Lan R, Girard C, Rochefort J, Le Pelletier F, Leroux-Villet C, Mares S, Millot S, Zlowodzki AS, Sibaud V, Tessier MH, Vaillant L, Fricain JC, Samimi M. French guidelines for the management of oral lichen planus (excluding pharmacological therapy). Ann Dermatol Venereol 2022; 149:14-27. [PMID: 34238586 DOI: 10.1016/j.annder.2021.04.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2020] [Revised: 01/16/2021] [Accepted: 04/01/2021] [Indexed: 02/06/2023]
Abstract
INTRODUCTION Oral lichen is a chronic inflammatory disease for which diagnostic management and follow-up are heterogeneous given the absence of specific guidelines in France. Our objective was to develop French multidisciplinary guidelines for the management of oral lichen. MATERIALS AND METHODS Working groups from the Groupe d'Etude de la Muqueuse Buccale (GEMUB) formulated a list of research questions and the corresponding recommendations according to the "formal consensus" method for developing practice guidelines. These recommendations were submitted to a group of experts and the degree of agreement for each recommendation was assessed by a scoring group. RESULTS Twenty-two research questions, divided into 3 themes (nosological classification and initial assessment, induced oral lichenoid lesions, and follow-up) resulted in 22 recommendations. Initial biopsy for histology is recommended in the absence of reticulated lesions. Biopsy for direct immunofluorescence is recommended for ulcerated, erosive, bullous types and for diffuse erythematous gingivitis. Management should include a periodontal and dental check-up, and investigation for extra-oral lesions. Hepatitis C testing is recommended only if risk factors are present. Definitions, triggering factors and the management of "induced oral lichenoid lesions" were clarified. Oral lichen must be monitored by a practitioner familiar with the disease at least once a year, using objective tools. CONCLUSION This formalised consensus of multidisciplinary experts provides clinical practice guidelines on the management and monitoring of oral lichen.
Collapse
Affiliation(s)
- F Campana
- Aix Marseille Univ, APHM, INSERM, MMG, Hôpital de la Timone, Unité de chirurgie orale, 264 Rue Saint-Pierre, 13005 Marseille, France
| | - R Lan
- Aix Marseille Univ, APHM, CNRS, EFS, ADES, Hôpital de la Timone, Unité de chirurgie orale, 264 Rue Saint-Pierre, 13005 Marseille, France
| | - C Girard
- Dermatologie, CHU de Montpellier, 34295 Montpellier cedex, France
| | - J Rochefort
- Odontologie, Hôpital La Pitié Salpetrière - Université Paris Diderot, 47-83 Boulevard de l'Hôpital, 75013 Paris, France
| | - F Le Pelletier
- Anatomie Pathologique, Hôpital La Pitié-Salpêtrière, 47-83 Boulevard de l'Hôpital, 75013 Paris, France
| | - C Leroux-Villet
- Dermatologie, Hôpital Avicenne, 125 Rue de Stalingrad, 93000 Bobigny, France
| | - S Mares
- Chirurgie Maxillo-faciale, Hôpital La Pitié-Salpêtrière, 47-83 Boulevard de l'Hôpital, 75013 Paris, France
| | - S Millot
- Chirurgie Orale, CHU de Montpellier, 34295 Montpellier cedex, France
| | | | - V Sibaud
- Dermatologie, IUCT Oncopôle, 31000 Toulouse, France
| | - M-H Tessier
- Dermatologie, CHU de Nantes, 44000 Nantes, France
| | - L Vaillant
- Dermatologie, CHU de Tours, Université de Tours, 37000 Tours, France
| | - J-C Fricain
- Université de Bordeaux, INSERM U1026, service de chirurgie orale, CHU Bordeaux, 33000 Bordeaux, France
| | - M Samimi
- Dermatologie, CHU de Tours, Université de Tours, 37000 Tours, France.
| |
Collapse
|
10
|
Sassine S, Savoie-Robichaud M, Lin Y, Djani L, Cambron-Asselin C, Qaddouri M, Fadela Zekhnine S, Grzywacz K, Groleau V, Dirks M, Drouin É, Halac U, Marchand V, Girard C, Courbette O, Patey N, Dal Soglio D, Deslandres C, Jantchou P. A186 CHANGES IN THE CLINICAL PHENOTYPE AND BEHAVIOR OF PEDIATRIC LUMINAL CROHN’S DISEASE AT DIAGNOSIS IN THE LAST DECADE. J Can Assoc Gastroenterol 2022. [PMCID: PMC8859170 DOI: 10.1093/jcag/gwab049.185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background Crohn’s disease (CD) triggers are incompletely understood and the incidence of the disease has been increasing. Aims The aims of this study were to describe the trends in the clinical, endoscopic, histological, and laboratory characteristics of pediatric CD during the last decade and to describe the seasonal variation of disease presentation at diagnosis. Methods Patients under 18 years old and diagnosed between 2009 and 2019 were included. Patients clinical, endoscopic, histological, and laboratory data were collected from the medical records. Data were analyzed for the cohort as a whole and according to diagnostic periods (2009–2014 and 2015–2019) and seasons. Results 654 patients were included in the study. The total number of incident CD cases significantly increased yearly. Patients diagnosed between 2015 and 2019 were younger at diagnosis (OR: 2.30, p<0.0001), had more perianal diseases (OR= 2.30, p<0.001) and more intestinal biopsy granulomas (OR= 1.61, p=0.003) as compared to the 2009–2014 cohort. Also, there was a strong association between intestinal biopsy granulomas, young age at diagnosis and perianal fistulas or abscesses; the presence of granulomas was associated with greater perianal involvements (OR= 2.25, p<0.001) and younger age at diagnosis (OR = 0.90, p=0.0002). PCDAI and SES-CD scores at diagnosis, disease location and behavior and laboratory markers did not change over time. There were fewer CD diagnosis during winter. The highest vitamin D levels in patients occurred in summer and fall, but the majority of patients had, regardless of the season of diagnosis, severe vitamin D deficiency (the median vitamin D level was 60.0 nmol/L in summer and fall compared to 47.0 nmol/L in winter-spring, p=0.003). Vitamin D levels at diagnosis are inversely correlated with PCDAI (Pearson correlation coefficient = -0.19, p=0.03) and SES-CD (-0.20, p=0.04). Patients diagnosed in fall had lower PCDAI and SES-CD scores, less failure to thrive, less digestive symptoms and less extensive digestive involvement. Colonic disease was significantly more frequent during summer and fall (27.3% of patients diagnosed in summer and fall versus 18.2% of cases in winter and spring, p=0.01). Conclusions The disease phenotype has changed over the years and there are important seasonal trends in the frequency and severety of the disease suggesting possible disease triggers. Our findings provide interesting avenues for future research, such as identifying the clinical significance of granulomas, vitamin D deficiency and microbiota on pediatric CD activity. ![]()
PCDAI at diagnosis according to the season. Funding Agencies NoneFonds Recherche Santé Québec / Fondation du CHU Sainte-Justine
Collapse
Affiliation(s)
- S Sassine
- Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada
| | | | - Y Lin
- Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada
| | - L Djani
- Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada
| | - C Cambron-Asselin
- Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada
| | - M Qaddouri
- Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada
| | - S Fadela Zekhnine
- Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada
| | - K Grzywacz
- Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada
| | - V Groleau
- Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada
| | - M Dirks
- Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada
| | - É Drouin
- Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada
| | - U Halac
- Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada
| | - V Marchand
- Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada
| | - C Girard
- Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada
| | - O Courbette
- Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada
| | - N Patey
- Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada
| | - D Dal Soglio
- Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada
| | - C Deslandres
- Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada
| | - P Jantchou
- Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada
| |
Collapse
|
11
|
Sassine S, Djani L, Cambron-Asselin C, Savoie-Robichaud M, Lin Y, Fadela Zekhnine S, Qaddouri M, Grzywacz K, Groleau V, Dirks M, Drouin É, Halac U, Marchand V, Girard C, Courbette O, Patey N, Dal Soglio D, Deslandres C, Jantchou P. A187 RISK FACTORS OF CLINICAL RELAPSES IN PEDIATRIC LUMINAL CROHN’S DISEASE, A RETROSPECTIVE COHORT STUDY. J Can Assoc Gastroenterol 2022. [PMCID: PMC8859367 DOI: 10.1093/jcag/gwab049.186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Few risk factors are associated with the risk of relapses of Crohn’s disease in children.
Aims
The aims of this retrospective cohort study were to describe the rate of relapses in children with Crohn’s disease, its evolution over the past decade and to determine risk factors associated with relapse.
Methods
Patients under 18 years old and diagnosed between 2009 and 2019 were included. Patients clinical, endoscopic, histological, and laboratory characteristics, as well as their treatments, where collected from their medical records and the prospective CHU Sainte-Justine inflammatory bowel disease registry. Survival analyses and Cox regression models were used to assess the impact of those risk factors on relapse.
Results
639 patients were included. There was a decrease in the clinical relapse rate over the past decade: 70.9% of patients diagnosed between 2009 and 2014 experienced a relapse compared to 49.1% of patients diagnosed between 2015 and 2019 (p<0.0001). The following variables were associated with clinical relapse: female sex (adjusted hazard ratio (aHR)= 1.51, p=0.0009), high PCDAI (aHR= 1.02, p=0.04) and SES-CD (aHR= 1.03, p=0.03) scores at diagnosis, upper digestive tract involvement (aHR= 1.59, p=0.0003), exposure to oral 5-ASA (aHR= 1.91, p=0.0003), use of immunomodulatory agents compared to TNF-alpha inhibitors (methotrexate aHR= 1.91, p=0.0006; thiopurines aHR= 2.06, p<0.0001), presence of granulomas (aHR= 1.27, p=0.04) and increased eosinophils on intestinal biopsies (aHR= 1.34, p=0.02), high levels of C-reactive protein (aHR= 1.01, p<0.0001) and fecal calprotectin (aHR=1.09, p<0.0001) during clinical remission and low serum infliximab levels during maintenance (aHR for mean serum infliximab level under 7ug/mL = 2.48, p=0.005).
Conclusions
Relapse risk was significantly associated with baseline clinical, endoscopic, histological and laboratory data and treatment strategies. These results could help better select treatment options for pediatric Crohn’s disease at induction and maintenance.
Kaplan-Meier curve representing patients time to relapse according to the mean infliximab level in post-induction.
Funding Agencies
NoneFonds Recherche Santé Québec / Fondation du CHU Sainte-Justine
Collapse
Affiliation(s)
- S Sassine
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - L Djani
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - C Cambron-Asselin
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - M Savoie-Robichaud
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - Y Lin
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - S Fadela Zekhnine
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - M Qaddouri
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - K Grzywacz
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - V Groleau
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - M Dirks
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - É Drouin
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - U Halac
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - V Marchand
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - C Girard
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - O Courbette
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - N Patey
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - D Dal Soglio
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - C Deslandres
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - P Jantchou
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| |
Collapse
|
12
|
Sassine S, Fadela Zekhnine S, Qaddouri M, Djani L, Cambron-Asselin C, Savoie-Robichaud M, Lin Y, Grzywacz K, Groleau V, Dirks M, Drouin É, Halac U, Marchand V, Girard C, Courbette O, Patey N, Dal Soglio D, Deslandres C, Jantchou P. A188 FACTORS ASSOCIATED WITH CLINICAL REMISSION IN PEDIATRIC LUMINAL CROHN’S DISEASE: A RETROSPECTIVE COHORT STUDY. J Can Assoc Gastroenterol 2022. [PMCID: PMC8859212 DOI: 10.1093/jcag/gwab049.187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
The natural evolution of Crohn’s disease is incompletely understood in the pediatric population. Data on factors influencing time-to-remission are very limited in the literature.
Aims
The aim of this retrospective cohort study was to describe the time to clinical remission in children with Crohn’s disease as well as changes over the past decade and to identify factors associated with time to clinical remission.
Methods
Patients under 18 years old diagnosed between 2009 and 2019 were included. All data were collected from the patients’ medical records and the CHU Sainte-Justine inflammatory bowel disease registry. Survival analyses and linear regression models were used to assess the impact of clinical, laboratory, endoscopic, histological and therapeutic factors on time to clinical remission.
Results
654 patients were included in the study. There was no change in the time to clinical remission over the past decade. Female sex in adolescents (ajusted bêta regression coefficient (aβ)= 31.8 days, p= 0.02), upper digestive tract involvement (aβ= 46.4 days, p= 0.04), perianal disease (aβ= 32.2 days, p= 0.04), presence of active inflammation on biopsies (aβ= 46.7 days, p= 0.01) and oral 5-ASA exposure (aβ=56.6 days, p= 0.002) were all associated with longer time to clinical remission. However, antibiotic exposure (aβ= -29.3 days, p=0.04), increased eosinophils on biopsies (aβ= -29.6 days, p=0.008) and combination of exclusive enteral nutrition and TNF- alpha inhibitors as induction therapy (aβ= -36.8, p=0.04) were associated with shorter time to clinical remission.
Conclusions
Time to clinical remission did not improve during the decade and was associated with baseline clinical and histological data and treatment strategies. Combination of enteral nutrition and TNF-alpha inhibitors was associated with faster clinical remission.
Kaplan-Meier curve representing the time to clinical remission of patients according to the first induction treatment administered.
Funding Agencies
NoneFonds Recherche Santé Québec / Fondation du CHU Sainte-Justine
Collapse
Affiliation(s)
- S Sassine
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - S Fadela Zekhnine
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - M Qaddouri
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - L Djani
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - C Cambron-Asselin
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - M Savoie-Robichaud
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - Y Lin
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - K Grzywacz
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - V Groleau
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - M Dirks
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - É Drouin
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - U Halac
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - V Marchand
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - C Girard
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - O Courbette
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - N Patey
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - D Dal Soglio
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - C Deslandres
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| | - P Jantchou
- Centre Hospitalier Universitaire Sainte-Justine Centre de Recherche, Montreal, QC, Canada
| |
Collapse
|
13
|
Yee LM, McGee P, Bailit JL, Wapner RJ, Varner MW, Thorp JM, Caritis SN, Prasad M, Tita AT, Saade GR, Sorokin Y, Rouse DJ, Blackwell SC, Tolosa JE, Mallett G, Grobman W, Ramos-Brinson M, Roy A, Stein L, Campbell P, Collins C, Jackson N, Dinsmoor M, Senka J, Paychek K, Peaceman A, Talucci M, Zylfijaj M, Reid Z, Leed R, Benson J, Forester S, Kitto C, Davis S, Falk M, Perez C, Hill K, Sowles A, Postma J, Alexander S, Andersen G, Scott V, Morby V, Jolley K, Miller J, Berg B, Dorman K, Mitchell J, Kaluta E, Clark K, Spicer K, Timlin S, Wilson K, Moseley L, Leveno K, Santillan M, Price J, Buentipo K, Bludau V, Thomas T, Fay L, Melton C, Kingsbery J, Benezue R, Simhan H, Bickus M, Fischer D, Kamon T, DeAngelis D, Mercer B, Milluzzi C, Dalton W, Dotson T, McDonald P, Brezine C, McGrail A, Latimer C, Guzzo L, Johnson F, Gerwig L, Fyffe S, Loux D, Frantz S, Cline D, Wylie S, Iams J, Wallace M, Northen A, Grant J, Colquitt C, Rouse D, Andrews W, Moss J, Salazar A, Acosta A, Hankins G, Hauff N, Palmer L, Lockhart P, Driscoll D, Wynn L, Sudz C, Dengate D, Girard C, Field S, Breault P, Smith F, Annunziata N, Allard D, Silva J, Gamage M, Hunt J, Tillinghast J, Corcoran N, Jimenez M, Ortiz F, Givens P, Rech B, Moran C, Hutchinson M, Spears Z, Carreno C, Heaps B, Zamora G, Seguin J, Rincon M, Snyder J, Farrar C, Lairson E, Bonino C, Smith W, Beach K, Van Dyke S, Butcher S, Thom E, Rice M, Zhao Y, Momirova V, Palugod R, Reamer B, Larsen M, Spong C, Tolivaisa S, VanDorsten J. Differences in obstetrical care and outcomes associated with the proportion of the obstetrician's shift completed. Am J Obstet Gynecol 2021; 225:430.e1-430.e11. [PMID: 33812810 DOI: 10.1016/j.ajog.2021.03.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2021] [Revised: 03/14/2021] [Accepted: 03/26/2021] [Indexed: 10/21/2022]
Abstract
BACKGROUND Understanding and improving obstetrical quality and safety is an important goal of professional societies, and many interventions such as checklists, safety bundles, educational interventions, or other culture changes have been implemented to improve the quality of care provided to obstetrical patients. Although many factors contribute to delivery decisions, a reduced workload has addressed how provider issues such as fatigue or behaviors surrounding impending shift changes may influence the delivery mode and outcomes. OBJECTIVE The objective was to assess whether intrapartum obstetrical interventions and adverse outcomes differ based on the temporal proximity of the delivery to the attending's shift change. STUDY DESIGN This was a secondary analysis from a multicenter obstetrical cohort in which all patients with cephalic, singleton gestations who attempted vaginal birth were eligible for inclusion. The primary exposure used to quantify the relationship between the proximity of the provider to their shift change and a delivery intervention was the ratio of time from the most recent attending shift change to vaginal delivery or decision for cesarean delivery to the total length of the shift. Ratios were used to represent the proportion of time completed in the shift by normalizing for varying shift lengths. A sensitivity analysis restricted to patients who were delivered by physicians working 12-hour shifts was performed. Outcomes chosen included cesarean delivery, episiotomy, third- or fourth-degree perineal laceration, 5-minute Apgar score of <4, and neonatal intensive care unit admission. Chi-squared tests were used to evaluate outcomes based on the proportion of the attending's shift completed. Adjusted and unadjusted logistic models fitting a cubic spline (when indicated) were used to determine whether the frequency of outcomes throughout the shift occurred in a statistically significant, nonlinear pattern RESULTS: Of the 82,851 patients eligible for inclusion, 47,262 (57%) had ratio data available and constituted the analyzable sample. Deliveries were evenly distributed throughout shifts, with 50.6% taking place in the first half of shifts. There were no statistically significant differences in the frequency of cesarean delivery, episiotomy, third- or fourth-degree perineal lacerations, or 5-minute Apgar scores of <4 based on the proportion of the shift completed. The findings were unchanged when evaluated with a cubic spline in unadjusted and adjusted logistic models. Sensitivity analyses performed on the 22.2% of patients who were delivered by a physician completing a 12-hour shift showed similar findings. There was a small increase in the frequency of neonatal intensive care unit admissions with a greater proportion of the shift completed (adjusted P=.009), but the findings did not persist in the sensitivity analysis. CONCLUSION Clinically significant differences in obstetrical interventions and outcomes do not seem to exist based on the temporal proximity to the attending physician's shift change. Future work should attempt to directly study unit culture and provider fatigue to further investigate opportunities to improve obstetrical quality of care, and additional studies are needed to corroborate these findings in community settings.
Collapse
|
14
|
Samaran Q, Girard C, Lerisson M, Boissin C, Jossien A, Serre I, Guillot B. [Granulomatous lung disease induced by kayexalate inhalation during immunotherapy for metastatic melanoma]. Rev Mal Respir 2021; 38:664-668. [PMID: 34024647 DOI: 10.1016/j.rmr.2021.04.016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2020] [Accepted: 04/15/2021] [Indexed: 11/16/2022]
Abstract
INTRODUCTION When a patient treated by immune checkpoint inhibitors for metastatic melanoma presents with pulmonary symptoms, several diagnoses are possible. We report a case of acute granulomatous lung disease secondary to repeated kayexalate inhalations, and probably stimulated by immunotherapy. CASE REPORT A patient treated with pembrolizumab and then ipilimumab presented with fever and acute shortness of breath. His pulmonary symptoms got progressively worse, leading to an acute respiratory distress syndrome. Chest CT displayed a pattern of non-specific organized pneumonia. Pulmonary infection, tumor progression, specific immune-related lung toxicity and immunotherapy-induced sarcoidosis were discussed. Histopathological examination of a lung biopsy showed a foreign body granulomatous macrophage reaction associated with crystalline, basophilic, purple and laminated elements, evoking kayexalate particles. These elements helped rewrite the diagnosis and confirmed a kayexalate-induced granulomatous lung disease secondary to repeated aspiration. The patient's respiratory condition got better following discontinuation of kayexalate together with systemic corticosteroids. Symptoms relapsed with resumption of the immunotherapy but were controlled with the addition of a new course of prolonged systemic corticosteroid therapy. We can hypothesize that immunotherapy played a role in the recurrence of the granulomatous lung reaction, or that there was an association between an aspiration pneumonia and an immunotherapy-induced lung toxicity. CONCLUSION Facing respiratory symptoms during immunotherapy, the treatment may be the cause, but lung biopsy should be performed rapidly to arrive to a certain diagnosis.
Collapse
Affiliation(s)
- Q Samaran
- Département de dermatologie, CHRU de Montpellier et université de Montpellier, Montpellier, France.
| | - C Girard
- Département de dermatologie, CHRU de Montpellier et université de Montpellier, Montpellier, France
| | - M Lerisson
- Département de dermatologie, CHRU de Montpellier et université de Montpellier, Montpellier, France
| | - C Boissin
- Département de pneumologie, CHRU de Montpellier et université de Montpellier, Montpellier, France
| | - A Jossien
- Département de pneumologie, CHRU de Montpellier et université de Montpellier, Montpellier, France
| | - I Serre
- Département d'anatomie et de cytologie pathologiques, CHRU de Montpellier et université de Montpellier, Montpellier, France
| | - B Guillot
- Département de dermatologie, CHRU de Montpellier et université de Montpellier, Montpellier, France
| |
Collapse
|
15
|
Roux C, Sbidian E, Bouaziz JD, Kottler D, Joly P, Prost C, Samimi M, Seneschal J, Dupin N, Girard C, Le Cléach L, Oro S. Intérêt du thalidomide en traitement continu des érythèmes polymorphes chroniques. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
16
|
Douillard M, Schwob E, Muslin A, Secco L, Becquart O, Dereure O, Bessis D, Girard C. Aggravation d’une calciphylaxie après injections intra-lésionnelles de thiosulfate de sodium. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
17
|
Schwob E, Bessis D, Boursier G, Kottler D, Guillot B, Lerisson M, Girard C. PASS: a rare syndrome within the autoinflammatory diseases that still lacks a genetic marker. J Eur Acad Dermatol Venereol 2020; 34:e478-e480. [PMID: 32215958 DOI: 10.1111/jdv.16385] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2020] [Revised: 03/07/2020] [Accepted: 03/16/2020] [Indexed: 11/29/2022]
Affiliation(s)
- E Schwob
- Department of Dermatology, Saint-Eloi Hospital and Montpellier University Hospital, Montpellier, France
| | - D Bessis
- Department of Dermatology, Saint-Eloi Hospital and Montpellier University Hospital, Montpellier, France
| | - G Boursier
- INSERM, Department of Medical Genetics, Rare Diseases and Personalized Medicine, CEREMAIA, CHU Montpellier, University of Montpellier, Montpellier, France
| | - D Kottler
- Division of Dermatology, Bichat Hospital, Paris, France
| | - B Guillot
- Department of Dermatology, Saint-Eloi Hospital and Montpellier University Hospital, Montpellier, France
| | - M Lerisson
- Department of Dermatology, Saint-Eloi Hospital and Montpellier University Hospital, Montpellier, France
| | - C Girard
- Department of Dermatology, Saint-Eloi Hospital and Montpellier University Hospital, Montpellier, France
| |
Collapse
|
18
|
Bergeret B, Secco LP, Pallure V, Daien C, Pers YM, Gottlieb J, Barete S, Girard C, Lipsker D, Bessis D. Palmoplantar lichen planus-like lupus erythematosus keratoderma: an underrecognized and distinctive cutaneous manifestation of systemic or subacute lupus erythematosus. J Eur Acad Dermatol Venereol 2020; 35:e124-e126. [PMID: 32757396 DOI: 10.1111/jdv.16852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2020] [Revised: 07/22/2020] [Accepted: 07/30/2020] [Indexed: 11/26/2022]
Affiliation(s)
- B Bergeret
- Department of Dermatology, Saint-Eloi Hospital, University Hospital of Montpellier, Montpellier, France
| | - L-P Secco
- Department of Dermatology, Saint-Eloi Hospital, University Hospital of Montpellier, Montpellier, France.,Department of Pathology, Gui de Chauliac Hospital, University Hospital of Montpellier, Montpellier, France
| | - V Pallure
- Department of Dermatology, Saint-Eloi Hospital, University Hospital of Montpellier, Montpellier, France.,Department of Dermatology and Internal Medicine, Perpignan Hospital, Perpignan, France
| | - C Daien
- Department of Rheumatology, Lapeyronie Hospital, University Hospital of Montpellier, Montpellier, France
| | - Y-M Pers
- Department of Rheumatology, Lapeyronie Hospital, University Hospital of Montpellier, Montpellier, France
| | - J Gottlieb
- Department of Internal Medicine, Bicètre University Hospital, AP-HP, Paris, France
| | - S Barete
- Department of Dermatology, La Pitié Salpétrière University Hospital, AP-HP, Paris, France
| | - C Girard
- Department of Dermatology, Saint-Eloi Hospital, University Hospital of Montpellier, Montpellier, France.,INSERM U1058, Montpellier, France
| | - D Lipsker
- Department of Dermatology, Civil Hospital, University Hospital of Strasbourg, Strasbourg, France
| | - D Bessis
- Department of Dermatology, Saint-Eloi Hospital, University Hospital of Montpellier, Montpellier, France.,INSERM U1058, Montpellier, France
| | | |
Collapse
|
19
|
Santschi E, Younkin J, Girard C, Laverty S. Complex stifle injury in a foal. EQUINE VET EDUC 2020. [DOI: 10.1111/eve.13063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- E. Santschi
- Department of Clinical Sciences Kansas State University Manhattan Kansas USA
| | - J. Younkin
- Department of Clinical Sciences Kansas State University Manhattan Kansas USA
| | - C. Girard
- Comparative Orthopedic Research Laboratory Department of Clinical Sciences Faculté de Médecine Vétérinaire Université de Montréal Saint‐Hyacinthe Québec Canada
| | - S. Laverty
- Comparative Orthopedic Research Laboratory Department of Clinical Sciences Faculté de Médecine Vétérinaire Université de Montréal Saint‐Hyacinthe Québec Canada
| |
Collapse
|
20
|
Letarouilly JG, Pariente B, Staumont-Sallé D, Goupille P, Claudepierre P, Varin S, Lanot S, Dernis E, Pascart T, Banneville B, Baudart P, Gombert B, Bauer E, Plastaras L, Barbarot S, Felten R, Le Dantec L, Sultan-Bichat N, Girard C, Constantin A, Wendling D, Gaudin P, Jullien D, Pham T, Flipo RM. THU0393 INFLAMMATORY BOWEL DISEASES AMONG SECUKINUMAB-TREATED PATIENTS: 24 CASES FROM THE MISSIL REGISTRY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.2516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:An alert regarding about the tolerance of Interleukin 17 (IL-17) inhibitors has been issued from data of randomized controlled trials showing cases of de novo inflammatory bowel diseases (IBD). In a recent analysis of pooled data from 21 clinical trials, cases of IBD events (including Crohn’s disease (CD), ulcerative colitis (UC) and inflammatory bowel disease unclassified (IBDU)) were uncommon (1). Yet, real-world data are lacking.Objectives:To describe real-world data about patients treated by IL-17 inhibitors developing new onset IBD (CD or UC).Methods:A French national registry called MISSIL was started in February 2018 to collect the cases of patients treated by IL-17 inhibitors developing new onset IBD. This registry is conducted by rheumatologist, dermatologist and gastroenterologist learned societies specialized on immune-mediated inflammatory diseases. In France, secukinumab (SEK) has been granted market authorization since June 2016 and ixekizumab since April 2018.Results:24 cases under SEK were reported between February 2018 and January 2020: 3 patients with psoriasis and 21 patients with spondylwoarthritis. There were 20 patients with new onset CD and 4 with UC. Mean age was 51.7 ± 15.7 years old and 12/24 were female; 10 presented an axial spondyloarthritis, 5 a peripheral spondyloarthritis and 6 both,13/17 were HLA-B27 positive,7/19 had a radiographic sacroiliitis and 11/17 a MRI sacroiliitis. Only 2 were biological Disease-modifying antirheumatic drug (bDMARD)-naïve. Crohn’s disease was mainly located at the ileum, colon and rectum. The median time to onset of symptoms was 2 (1-6) months. The main symptoms were diarrhea, nausea and vomiting and loss of weight. Median CRP at the onset of symptoms was 68 mg/L (41-140.5); 21 patients underwent biopsies, 12 were in favor of CD. IL-17 inhibitors were consistently stopped. Patients were treated by corticosteroids (16/24), mesalazine (7/24), methotrexate (3/24), thiopurines (2/24), infliximab (9/243), adalimumab (3/24), golimumab (2/24), ustekinumab (5/24). The evolution was favorable under treatment with complete resolution (4/24), improvement (11/24) or stabilization (5/24). 3 patients worsened under treatment and 1 died (massive myocardial infarction).Conclusion:IBD flare in patients treated with IL-17 inhibitors are rare and lead to discuss the potential iatrogenic role of IL-17 inhibitor drugs. Further cases are needed to better characterize this complication. A case-control study will be conducted to identify patients at risk to develop IBD under IL-17 inhibitor.References:[1]Reich et al. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis. 2019;78:473-479Disclosure of Interests:Jean-Guillaume Letarouilly Grant/research support from: Research grant from Pfizer, Benjamin Pariente: None declared, Delphine Staumont-Sallé Speakers bureau: Lilly, Novartis, Philippe Goupille Grant/research support from: AbbVie, Amgen, Biogen, BMS, Celgene, Chugai, Lilly, Janssen, Medac, MSD France, Nordic Pharma, Novartis, Pfizer, Sanofi and UCB, Consultant of: AbbVie, Amgen, Biogen, BMS, Celgene, Chugai, Lilly, Janssen, Medac, MSD France, Nordic Pharma, Novartis, Pfizer, Sanofi and UCB, Speakers bureau: AbbVie, Amgen, Biogen, BMS, Celgene, Chugai, Lilly, Janssen, Medac, MSD France, Nordic Pharma, Novartis, Pfizer, Sanofi and UCB, Pascal Claudepierre Speakers bureau: Janssen, Novartis, Lilly, Stephane Varin: None declared, Sylvain Lanot: None declared, Emmanuelle Dernis Speakers bureau: Lilly, Novartis, Tristan Pascart Speakers bureau: Novartis, Lilly, Beatrice Banneville Speakers bureau: Lilly, Novartis, Pauline Baudart: None declared, Bruno Gombert: None declared, Elodie BAUER: None declared, Laurianne Plastaras: None declared, Sébastien Barbarot: None declared, Renaud FELTEN: None declared, Loïc Le Dantec: None declared, Nathalie Sultan-Bichat: None declared, Céline Girard: None declared, Arnaud Constantin Grant/research support from: Study was sponsored by Sanofi Genzyme, Consultant of: Consulting fees from Abbvie, BMS, Celgene, Gilead, Janssen, Lilly, Novartis, Pfizer, Roche, Sanofi, UCB, Daniel Wendling: None declared, Philippe Gaudin Speakers bureau: Lilly, Denis Jullien Speakers bureau: Lilly, Novartis, Thao Pham Speakers bureau: Novartis, Janssen, Lilly, Rene-Marc Flipo Speakers bureau: Novartis, Janssen, Lilly
Collapse
|
21
|
Muller J, Cardey B, Zedet A, Desingle C, Grzybowski M, Pomper P, Foley S, Harakat D, Ramseyer C, Girard C, Pudlo M. Synthesis, evaluation and molecular modelling of piceatannol analogues as arginase inhibitors. RSC Med Chem 2020; 11:559-568. [PMID: 33479657 PMCID: PMC7593889 DOI: 10.1039/d0md00011f] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2020] [Accepted: 03/29/2020] [Indexed: 11/21/2022] Open
Abstract
Arginase is involved in a wide range of pathologies including cardiovascular diseases and infectious diseases whilst it is also a promising target to improve cancer immunotherapy. To date, only a limited number of inhibitors of arginase have been reported. Natural polyphenols, among them piceatannol, are moderate inhibitors of arginase. Herein, we report our efforts to investigate catechol binding by quantum chemistry and generate analogues of piceatannol. In this work, we synthesized a novel series of amino-polyphenols which were then evaluated as arginase inhibitors. Their structure-activity relationships were elucidated by deep quantum chemistry modelling. 4-((3,4-Dihydroxybenzyl)amino)benzene-1,2-diol 3t displays a mixed inhibition activity on bovine and human arginase I with IC50 (K i) values of 76 (82) μM and 89 μM, respectively.
Collapse
Affiliation(s)
- J Muller
- PEPITE EA4267 , Univ. Bourgogne Franche-Comté , F-25000 Besançon , France . ; Tel: +(33) 381 665 542
| | - B Cardey
- Laboratoire Chrono-environnement (UMR CNRS 6249) , Univ. Bourgogne Franche-Comté , F-25000 Besançon , France
| | - A Zedet
- PEPITE EA4267 , Univ. Bourgogne Franche-Comté , F-25000 Besançon , France . ; Tel: +(33) 381 665 542
| | - C Desingle
- PEPITE EA4267 , Univ. Bourgogne Franche-Comté , F-25000 Besançon , France . ; Tel: +(33) 381 665 542
| | - M Grzybowski
- OncoArendi Therapeutics , PL02089 Warsaw , Poland
| | - P Pomper
- OncoArendi Therapeutics , PL02089 Warsaw , Poland
| | - S Foley
- Laboratoire Chrono-environnement (UMR CNRS 6249) , Univ. Bourgogne Franche-Comté , F-25000 Besançon , France
| | - D Harakat
- Institut de Chimie Moléculaire de Reims (UMR CNRS 7312) , Univ. Reims Champagne Ardenne , F-51000 Reims , France
| | - C Ramseyer
- Laboratoire Chrono-environnement (UMR CNRS 6249) , Univ. Bourgogne Franche-Comté , F-25000 Besançon , France
| | - C Girard
- PEPITE EA4267 , Univ. Bourgogne Franche-Comté , F-25000 Besançon , France . ; Tel: +(33) 381 665 542
| | - M Pudlo
- PEPITE EA4267 , Univ. Bourgogne Franche-Comté , F-25000 Besançon , France . ; Tel: +(33) 381 665 542
| |
Collapse
|
22
|
Grodner C, Beauchet A, Fougerousse A, Quiles‐Tsimaratos N, Perrot J, Barthelemy H, Parier J, Maccari F, Beneton N, Bouilly‐Auvray D, Ruer‐Mulard M, Boulard C, Jacobzone C, Thomas‐Beaulieu D, Pourchot D, Méry‐Bossard L, Chaby G, Girard C, Duval‐Modeste A, Vermersch‐Langlin A, Delaunay J, Marc S, Kemula M, Steff M, Bilan P, Liégeon A, Aubert H, Solyga B, Kluger N, Mahé E. Tattoo complications in treated and non‐treated psoriatic patients. J Eur Acad Dermatol Venereol 2020; 34:888-896. [DOI: 10.1111/jdv.15975] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2019] [Accepted: 09/04/2019] [Indexed: 11/27/2022]
Affiliation(s)
- C. Grodner
- Dermatology Department Hôpital Victor Dupouy Argenteuil France
| | - A. Beauchet
- Public Health Department Hôpital Ambroise Paré Boulogne‐Billancourt France
| | - A.‐C. Fougerousse
- Dermatology Department Hôpital d'Instruction des Armées Bégin Saint Mandé France
| | | | - J.‐L. Perrot
- Dermatology Department CHU Saint‐Etienne Saint‐Etienne France
| | - H. Barthelemy
- Dermatology Department Centre Hospitalier d'Auxerre Auxerre France
| | - J. Parier
- Private Office La Varenne St Hilaire France
| | - F. Maccari
- Private Office La Varenne St Hilaire France
| | - N. Beneton
- Dermatology Department Centre Hospitalier du Mans Le Mans France
| | - D. Bouilly‐Auvray
- Dermatology Department Centre Hospitalier Universitaire de Dijon Dijon France
| | | | - C. Boulard
- Dermatology Department Hôpital Jacques Monod Le Havre Cedex France
| | - C. Jacobzone
- Dermatology Department Centre Hospitalier de Lorient Lorient France
| | - D. Thomas‐Beaulieu
- Dermatology Department Centre Hospitalier Intercommunal de Poissy/Saint‐Germain‐en‐Laye Saint‐Germain‐en‐Laye France
| | - D. Pourchot
- Dermatology Department Centre Hospitalier Intercommunal de Poissy/Saint‐Germain‐en‐Laye Saint‐Germain‐en‐Laye France
| | - L. Méry‐Bossard
- Dermatology Department Centre Hospitalier Intercommunal de Poissy/Saint‐Germain‐en‐Laye Saint‐Germain‐en‐Laye France
| | - G. Chaby
- Dermatology Department Hôpital Sud Amiens France
| | - C. Girard
- Dermatology Department Centre Hospitalier Universitaire de Montpellier Montpellier France
| | - A.‐B. Duval‐Modeste
- Dermatology Department Centre Hospitalier Universitaire Charles‐Nicolle Rouen France
| | | | | | - S. Marc
- Dermatology Department Hôpital François Quesnay Mantes La Jolie France
| | | | - M. Steff
- Dermatology Department Hôpital Intercommunal Robert‐Ballanger Aulnay‐sous‐Bois France
| | - P. Bilan
- Dermatology Department Hôpital Intercommunal Robert‐Ballanger Aulnay‐sous‐Bois France
| | - A.‐L. Liégeon
- Dermatology Department Hôpital de Valence Valence France
| | - H. Aubert
- Dermatology Department Centre Hospitalier Universitaire de Nantes Nantes France
| | - B. Solyga
- Private Office Fontenay‐sous‐Bois France
| | - N. Kluger
- Dermatology Department, Allergology, and Venereology University of Helsinki and Helsinki University Central Hospital Helsinki Finland
- Dermatology Department Tattoo Consultation Centre Hospitalier Universitaire Bichat‐Claude Bernard Assistance Publique‐Hôpitaux de Paris Paris France
| | - E. Mahé
- Dermatology Department Hôpital Victor Dupouy Argenteuil France
| | | |
Collapse
|
23
|
Husson B, Barbe C, Hegazy S, Seneschal J, Aubin F, Mahé E, Jullien D, Sbidian E, D'Incan M, Conrad C, Brenaut E, Girard C, Richard M, Bachelez H, Viguier M. Efficacy and safety of
TNF
blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau. J Eur Acad Dermatol Venereol 2020; 34:2330-2338. [DOI: 10.1111/jdv.16265] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2019] [Accepted: 01/21/2020] [Indexed: 12/12/2022]
Affiliation(s)
- B. Husson
- Dermatology Department Hôpital Robert‐Debré Reims France
| | - C. Barbe
- Clinical Research Unit Hôpital Robert‐Debré Reims France
| | - S. Hegazy
- Dermatology Department Hôpital Larrey Toulouse France
| | - J. Seneschal
- Dermatology Department National Reference Center for Rare Skin Diseases Hôpital Saint‐André Bordeaux France
| | - F. Aubin
- Dermatology Department Centre Hospitalo‐Universitaire (CHU) Besançon France
| | - E. Mahé
- Dermatology Department Centre Hospitalier (CH) Argenteuil France
| | - D. Jullien
- Clinical Immunology Department CH Lyon‐Sud Lyon France
| | - E. Sbidian
- Dermatology Department Hôpital Henri‐Mondor Créteil France
| | - M. D'Incan
- Dermatology Department CHU Estaing Clermont‐Ferrand France
| | - C. Conrad
- Dermatology Department Lausanne University Hospital CHUV Lausanne Switzerland
| | | | - C. Girard
- Dermatology Department CHU Lapeyronie Montpellier France
| | - M.A. Richard
- Dermatology Department CEReSS‐EA 3279 Research Center in Health Services and Quality of Life Aix Marseille University Universitary Hospital Timone Assistance Publique Hôpitaux de Marseille Marseille France
| | - H. Bachelez
- Université de Paris Paris France
- Dermatology Department Assistance Publique‐Hôpitaux de Paris Hôpital Saint‐Louis Paris France
- Laboratory of Genetics of Skin Diseases INSERM UMR1163 Institut Imagine Necker Hospital Paris France
| | - M. Viguier
- Dermatology Department Hôpital Robert‐Debré Reims France
| | | |
Collapse
|
24
|
Barroil M, Girard C, Lerisson M, Negroni V, Bertrand AS, Pallure V, Bessis D, Guillot B, Dereure O. [Use of rituximab in maintenance treatment of pemphigus: A retrospective series]. Ann Dermatol Venereol 2020; 147:173-178. [PMID: 31955970 DOI: 10.1016/j.annder.2019.08.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2018] [Revised: 03/31/2019] [Accepted: 08/05/2019] [Indexed: 11/26/2022]
Abstract
INTRODUCTION Rituximab (RTX), currently recommended as first-line treatment in moderate to severe pemphigus vulgaris (PV) and superficial pemphigus (PS) along with initial systemic steroids, may also be used as second-line or subsequent treatment, and this therapeutic strategy was investigated in a real-life monocentre retrospective survey. MATERIAL AND METHODS All patients treated between January 2010 and March 2018 with RTX as second-line or subsequent treatment for moderate to severe PV or PS and followed for at least one year were included. The main objective was to evaluate rates and times of complete clinical remission (CCR) after a first course of RTX. The secondary objectives consisted mainly of treatment safety, and frequency and time to relapse after the initial CCR. RESULTS The 24 patients selected received on average 2 cycles of RTX (i.e. 24 initial cycles and 24 additional cycles in all) over a mean follow-up period of 45 months. 18/24 (75%) patients achieved initial CCR within a mean 7.7 months. Despite at least one relapse in 13/18 initially responding patients regardless of relapse time, 59% (14/24) and 33% (8/24) were either in CCR and off treatment, or in partial remission, whether treated or untreated, according to the latest patient news, with an overall response rate of 92%. Safety was fair in these fragile patients. DISCUSSION AND CONCLUSION This survey of the practical use of RTX confirms its interest in moderate to severe pemphigus as a second-line or subsequent treatment, a situation that probably remains relevant even if this molecule is increasingly used as first-line therapy.
Collapse
Affiliation(s)
- M Barroil
- Département de Dermatologie et INSERM U1058 « pathogénèse et contrôle des infections chroniques », université de Montpellier, hôpital Saint-Éloi, 80, avenue Augustin-Fliche, Montpellier cedex 5, France
| | - C Girard
- Département de Dermatologie et INSERM U1058 « pathogénèse et contrôle des infections chroniques », université de Montpellier, hôpital Saint-Éloi, 80, avenue Augustin-Fliche, Montpellier cedex 5, France
| | - M Lerisson
- Département de Dermatologie et INSERM U1058 « pathogénèse et contrôle des infections chroniques », université de Montpellier, hôpital Saint-Éloi, 80, avenue Augustin-Fliche, Montpellier cedex 5, France
| | - V Negroni
- Département de Dermatologie et INSERM U1058 « pathogénèse et contrôle des infections chroniques », université de Montpellier, hôpital Saint-Éloi, 80, avenue Augustin-Fliche, Montpellier cedex 5, France
| | - A-S Bertrand
- Département de Dermatologie et INSERM U1058 « pathogénèse et contrôle des infections chroniques », université de Montpellier, hôpital Saint-Éloi, 80, avenue Augustin-Fliche, Montpellier cedex 5, France
| | - V Pallure
- Département de Dermatologie et INSERM U1058 « pathogénèse et contrôle des infections chroniques », université de Montpellier, hôpital Saint-Éloi, 80, avenue Augustin-Fliche, Montpellier cedex 5, France
| | - D Bessis
- Département de Dermatologie et INSERM U1058 « pathogénèse et contrôle des infections chroniques », université de Montpellier, hôpital Saint-Éloi, 80, avenue Augustin-Fliche, Montpellier cedex 5, France
| | - B Guillot
- Département de Dermatologie et INSERM U1058 « pathogénèse et contrôle des infections chroniques », université de Montpellier, hôpital Saint-Éloi, 80, avenue Augustin-Fliche, Montpellier cedex 5, France
| | - O Dereure
- Département de Dermatologie et INSERM U1058 « pathogénèse et contrôle des infections chroniques », université de Montpellier, hôpital Saint-Éloi, 80, avenue Augustin-Fliche, Montpellier cedex 5, France.
| |
Collapse
|
25
|
Sigg N, Delaunay J, Livideanu CB, Aubin F, Bachelez H, Charles J, Dupuy A, Girard C, Goujon-Henry C, D’Incan M, Jullien D, Ly S, Maillard H, Misery L, Montaudié H, Parier J, Perrussel M, Richard MA, Seneschal J, Staumont-Salle D, Viguier M, Bénéton N. Eruptions cutanées dysimmunitaires et inflammatoires au cours d’un traitement par anti IL-17 dans le psoriasis: 47 cas. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
26
|
Phan C, Beauchet A, Burztejn A, Severino-Freire M, Mazereeuw-Hautier J, Barbarot S, Girard C, Lasek A, Reguiai Z, Sassolas B, Droitcourt C, Perrussel M, Hadj-Rabia S, Mallet S, Phan A, Lacour JP, Bourrat E, Aubin F, Mahé E. Enfants atteints de psoriasis issus de la cohorte BIPE : évaluation de l’éligibilité des enfants traités par biothérapie dans la vie courante pour des études cliniques de phase III. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.520] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
27
|
Grodner C, Beauchet A, Fougerousse AC, Quiles-Tsimaratos N, Perrot JL, Barthelemy H, Parier J, Maccari F, Bénéton N, Bouilly-Auvray D, Ruer-Mulard M, Boulard C, Jacobzone C, Thomas-Beaulieu D, Méry-Bossard L, Pourchot D, Chaby G, Girard C, Duval-Modeste AB, Vermersch-Langlin A, Delaunay J, Marc S, Kemula M, Sigal ML, Amy de la Breteque M, Steff M, Bilan P, Liégeon AL, Aubert H, Solyga B, Kluger N, Mahé E. Complications des tatouages chez les patients psoriasiques avec ou sans traitements. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
28
|
Fougerousse A, Maccari F, Beauchet A, Parier J, Boulard C, Becherel P, Quiles‐Tsimaratos N, Le Guyadec T, Thomas‐Beaulieu D, Halioua B, Begon E, Bastien M, Perrot J, Pallure V, Bilan P, Steff M, Pfister P, Vermersch‐Langlin A, Boyé T, Mery‐Bossard L, Maillard H, Kemula M, Girard C, Poiraud C, Monfort J, Kupfer‐Bessaguet I, Perrussel M, Lons‐Danic D, Sultan N, Lorier E, Zeitoun M, Wagner L, Gabison G, Mahé E. Factors that may influence the choice for initiating apremilast or methotrexate treatment for psoriasis in real‐world clinical setting. J Eur Acad Dermatol Venereol 2019; 33:e476-e478. [DOI: 10.1111/jdv.15804] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- A.‐C. Fougerousse
- Dermatology Department Hôpital d'Instruction des Armées Bégin Saint Mandé France
| | - F. Maccari
- Private Office La Varenne Saint Hilaire France
| | - A. Beauchet
- Department of Public Health Centre Hospitalier Universitaire Ambroise Paré APHP & UVSQ Université Paris‐Saclay Boulogne‐Billancourt France
| | - J. Parier
- Private Office La Varenne Saint Hilaire France
| | - C. Boulard
- Dermatology Department Hôpital du Havre Montivilliers France
| | - P.‐A. Becherel
- Dermatology Department Hôpital Privé d'Antony Antony France
| | | | - T. Le Guyadec
- Dermatology Department Hôpital d'Instruction des Armées Percy Clamart France
| | - D. Thomas‐Beaulieu
- Dermatology Department Centre Hospitalier Intercommunal Poissy‐Saint Germain en Laye Poissy France
| | | | - E. Begon
- Dermatology Department Hôpital René Dubos Pontoise France
| | | | - J.‐L. Perrot
- Dermatology Department Centre Hospitalier Universitaire Saint Etienne France
| | - V. Pallure
- Dermatology Department Centre Hospitalier Perpignan France
| | - P. Bilan
- Dermatology Department Centre Hospitalier Robert Ballanger Aulnay‐sous‐Bois France
| | - M. Steff
- Dermatology Department Centre Hospitalier Robert Ballanger Aulnay‐sous‐Bois France
| | | | | | - T. Boyé
- Dermatology Department Hôpital d'Instruction des Armées Sainte Anne Toulon France
| | - L. Mery‐Bossard
- Dermatology Department Centre Hospitalier François Quesnay Mantes la Jolie France
| | - H. Maillard
- Dermatology Department Centre Hospitalier Le Mans France
| | | | - C. Girard
- Dermatology Department Centre Hospitalier Universitaire Sainte Eloi Montpellier France
| | - C. Poiraud
- Dermatology Department Centre Hospitalier La Roche sur Yon France
| | - J.‐B. Monfort
- Dermatology Department Centre Hospitalier Universitaire Tenon Paris France
| | | | | | - D. Lons‐Danic
- Dermatology Department Hôpital Saint Joseph Paris France
| | - N. Sultan
- Dermatology Department Centre Hospitalier Gabriel Martin Saint‐Paul France
| | | | | | | | | | - E. Mahé
- Dermatology Department Hôpital Victor Dupouy Argenteuil France
| | | |
Collapse
|
29
|
Elamari H, Ouerghui A, Ammari F, Girard C. A Simple Efficient Click Synthesis of Novel Crown Ethers Containing 1,2,3-Triazole Moieties. Russ J Org Chem 2019. [DOI: 10.1134/s1070428019110228] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
30
|
Bertrand AS, Dereure O, Girard C, Bessis D, Guillot B. Place du rituximab dans le traitement de la pemphigoïde des muqueuses. Ann Dermatol Venereol 2019; 146:659-661. [DOI: 10.1016/j.annder.2019.07.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2017] [Revised: 03/01/2019] [Accepted: 07/05/2019] [Indexed: 11/27/2022]
|
31
|
Rathore M, Girard C, Ohanna M, Tichet M, Ben Jouira R, Garcia E, Larbret F, Gesson M, Audebert S, Lacour JP, Montaudié H, Prod'Homme V, Tartare-Deckert S, Deckert M. Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)/NF-κB signaling pathway. Oncogene 2019; 38:5873-5889. [PMID: 31253871 DOI: 10.1038/s41388-019-0848-9] [Citation(s) in RCA: 55] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2018] [Revised: 03/30/2019] [Accepted: 04/28/2019] [Indexed: 01/23/2023]
Abstract
Cutaneous melanoma is one of the most aggressive cancers characterized by a high plasticity, a propensity for metastasis, and drug resistance. Melanomas are composed of phenotypically diverse subpopulations of tumor cells with heterogeneous molecular profiles that reflect intrinsic invasive abilities. In an attempt to identify novel factors of the melanoma invasive cell state, we previously investigated the nature of the invasive secretome by using a comparative proteomic approach. Here, we have extended this analysis to show that PTX3, an acute phase inflammatory glycoprotein, is one such factor secreted by invasive melanoma to promote tumor cell invasiveness. Elevated PTX3 production was observed in the population of MITFlow invasive cells but not in the population of MITFhigh differentiated melanoma cells. Consistently, MITF knockdown increased PTX3 expression in MITFhigh proliferative and poorly invasive cells. High levels of PTX3 were found in tissues and blood of metastatic melanoma patients, and in BRAF inhibitor-resistant melanoma cells displaying a mesenchymal invasive MITFlow phenotype. Genetic silencing of PTX3 in invasive melanoma cells dramatically impaired migration and invasion in vitro and in experimental lung extravasation assay in xenografted mice. In contrast, addition of melanoma-derived or recombinant PTX3, or expression of PTX3 enhanced motility of low migratory cells. Mechanistically, autocrine production of PTX3 by melanoma cells triggered an IKK/NFκB signaling pathway that promotes migration, invasion, and expression of the EMT factor TWIST1. Finally, we found that TLR4 and MYD88 knockdown inhibited PTX3-induced melanoma cell migration, suggesting that PTX3 functions through a TLR4-dependent pathway. Our work reveals that tumor-derived PTX3 contributes to melanoma cell invasion via targetable inflammation-related pathways. In addition to providing new insights into the biology of melanoma invasive behavior, this study underscores the notion that secreted PTX3 represents a potential biomarker and therapeutic target in a subpopulation of MITFlow invasive and/or refractory melanoma.
Collapse
Affiliation(s)
- M Rathore
- Université Côte d'Azur, INSERM, C3M, Nice, France
- Equipe labellisée Ligue Contre le Cancer 2016, Nice, France
- The Hormel Institute, University of Minnesota, Austin, MN, USA
| | - C Girard
- Université Côte d'Azur, INSERM, C3M, Nice, France
- Equipe labellisée Ligue Contre le Cancer 2016, Nice, France
| | - M Ohanna
- Université Côte d'Azur, INSERM, C3M, Nice, France
- Equipe labellisée Ligue Contre le Cancer 2016, Nice, France
| | - M Tichet
- Université Côte d'Azur, INSERM, C3M, Nice, France
- Laboratory of Translational Oncology, ISREC, EPFL, Lausanne, Switzerland
| | - R Ben Jouira
- Université Côte d'Azur, INSERM, C3M, Nice, France
| | - E Garcia
- Université Côte d'Azur, INSERM, C3M, Nice, France
| | - F Larbret
- Université Côte d'Azur, INSERM, C3M, Nice, France
- Equipe labellisée Ligue Contre le Cancer 2016, Nice, France
| | - M Gesson
- Université Côte d'Azur, INSERM, C3M, Nice, France
| | - S Audebert
- Aix-Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France
| | - J-P Lacour
- Université Côte d'Azur, CHU Nice, Nice, France
| | - H Montaudié
- Université Côte d'Azur, CHU Nice, Nice, France
| | - V Prod'Homme
- Université Côte d'Azur, INSERM, C3M, Nice, France
- Equipe labellisée Ligue Contre le Cancer 2016, Nice, France
| | - S Tartare-Deckert
- Université Côte d'Azur, INSERM, C3M, Nice, France.
- Equipe labellisée Ligue Contre le Cancer 2016, Nice, France.
| | - M Deckert
- Université Côte d'Azur, INSERM, C3M, Nice, France.
- Equipe labellisée Ligue Contre le Cancer 2016, Nice, France.
| |
Collapse
|
32
|
Girard C, Fayolle K, Kerros S, Leriche F. Flow cytometric assessment of the antimicrobial properties of an essential oil mixture against Escherichia coli. J Anim Feed Sci 2019. [DOI: 10.22358/jafs/109687/2019] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
33
|
Phan C, Beauchet A, Burztejn A, Severino‐Freire M, Barbarot S, Girard C, Lasek A, Reguiai Z, Hadj‐Rabia S, Abasq C, Brenaut E, Droitcourt C, Perrussel M, Mallet S, Phan A, Lacour J, Khemis A, Bourrat E, Chaby G, Deborde R, Plantin P, Maruani A, Piram M, Maccari F, Fougerousse A, Kupfer‐Bessaguet I, Balguérie X, Barthelemy H, Martin L, Quiles‐Tsimaratos N, Mery‐Brossard L, Pallure V, Lons‐Danic D, Bouilly‐Auvray D, Beylot‐Barry M, Puzenat E, Aubin F, Mahé E. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis. J Eur Acad Dermatol Venereol 2019; 33:1984-1992. [DOI: 10.1111/jdv.15579] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2018] [Accepted: 02/27/2019] [Indexed: 02/06/2023]
|
34
|
Tournier A, Khemis A, Maccari F, Reguiai Z, Bégon E, Fougerousse AC, Amy de la Breteque M, Beneton N, Parier J, Boyé T, Avenel-Audran M, Girard C, Pallure V, Perrot JL, Bastien M, Mahé E, Beauchet A. Methotrexate efficacy and tolerance in plaque psoriasis. A prospective real-life multicentre study in France. Ann Dermatol Venereol 2019; 146:106-114. [DOI: 10.1016/j.annder.2018.11.011] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2018] [Revised: 08/28/2018] [Accepted: 11/21/2018] [Indexed: 12/28/2022]
|
35
|
Bessis D, Petit A, Battistella M, Bourrat E, Girard C, Pallure V, Marque M, Lacour J, Vitetta A, Bieth É, Selves J, Solassol J, Vendrell J. Naevoid acanthosis nigricans or RAVEN (rounded and velvety epidermal naevus) and mosaic
FGFR3
and
FGFR2
mutations. Br J Dermatol 2019; 180:955-957. [DOI: 10.1111/bjd.17581] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- D. Bessis
- Department of Dermatology and Competence Center for Rare Skin Diseases Saint‐Eloi Hospital, and University of Montpellier Montpellier France
- INSERM U1058 Montpellier France
| | - A. Petit
- Department of Dermatology Saint‐Louis Hospital, AP‐HP Paris France
| | - M. Battistella
- Department of Pathology Saint‐Louis Hospital, AP‐HP, Paris and University Paris Diderot, INSERM UMR_S1165 Paris France
| | - E. Bourrat
- Department of Paediatric Dermatology Robert‐Debré Hospital, AP‐HP Paris France
| | - C. Girard
- Department of Dermatology and Competence Center for Rare Skin Diseases Saint‐Eloi Hospital, and University of Montpellier Montpellier France
- INSERM U1058 Montpellier France
| | - V. Pallure
- Department of Dermatology and Internal Medicine Perpignan CH Perpignan France
| | - M. Marque
- Department of Dermatology Caremeau Hospital and University Hospital of Montpellier‐Nîmes Nîmes France
| | - J.‐P. Lacour
- Department of Dermatology and Reference Center for Rare Skin Diseases L'Archet 2 Hospital, and INSERM U 634, University of Nice Sophia‐Antipolis Nice France
| | - A. Vitetta
- Medical office 48 rue Gioffredo NiceFrance
| | - É. Bieth
- Department of Medical Genetics Purpan Hospital University Hospital of Toulouse Toulouse France
| | - J. Selves
- Department of Pathology University Institute of Cancer of Toulouse and INSERM UMR1037, University of Toulouse Toulouse France
| | - J. Solassol
- Laboratory of Solid Tumour Biology, Department of Pathology and Oncology Arnaud de Villeneuve Hospital and University of Montpellier Montpellier France
| | - J. Vendrell
- Laboratory of Solid Tumour Biology, Department of Pathology and Oncology Arnaud de Villeneuve Hospital and University of Montpellier Montpellier France
| |
Collapse
|
36
|
Reymann V, Vincent T, Bessis D, Dereure O, Girard C. Valeur ajoutée des dosages d’infliximab sanguin et d’anticorps anti-infliximab chez les patients psoriasiques. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
37
|
Amatore F, Viguier M, Beylot-Barry M, Mahé E, Staumont-Sallé D, Villani A, Picard-Gauci A, Girard C, Sbidian E, Bachelez H, Richard MA. Étude des prescriptions de biosimilaires de l’infliximab dans le psoriasis dans les services de dermatologie français. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
38
|
Bessis D, Bieth E, Selves J, Girard C, Solassol J, Vendrell J. Hamartome épidermique à type d’acanthosis nigricans : vers une corrélation phénotype–génotype ? Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
39
|
Alenezi F, Girard C, Guillot B, Bessis D, Du Thanh A, Dereure O. Le méthotrexate est-il vraiment efficace dans les lymphomes cutanés épidermotropes ? Une série rétrospective de 48 patients. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
40
|
Husson B, Barbe C, Hegazy S, Seneschal J, Aubin F, Mahé E, Jullien D, Sbidian E, d’Incan M, Conrad C, Brénault E, Girard C, Avenel-Audran M, Le Maître M, Modiano P, Quiles N, Zaraa I, Richard MA, Goujon C, Beneton N, Destoop J, Bachelez H, Viguier M. Efficacité et tolérance des traitements systémiques conventionnels dans le traitement du psoriasis pustuleux acral : étude française rétrospective sur 205 patients. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
41
|
Tita AT, Jablonski KA, Bailit JL, Grobman WA, Wapner RJ, Reddy UM, Varner MW, Thorp JM, Leveno KJ, Caritis SN, Iams JD, Saade G, Sorokin Y, Rouse DJ, Blackwell SC, Tolosa JE, Wallace M, Northen A, Grant J, Colquitt C, Mallett G, Ramos-Brinson M, Roy A, Stein L, Campbell P, Collins C, Jackson N, Dinsmoor M, Senka J, Paychek K, Peaceman A, Talucci M, Zylfijaj M, Reid Z, Leed R, Benson J, Forester S, Kitto C, Davis S, Falk M, Perez C, Hill K, Sowles A, Postma J, Alexander S, Andersen G, Scott V, Morby V, Jolley K, Miller J, Berg B, Dorman K, Mitchell J, Kaluta E, Clark K, Spicer K, Timlin S, Wilson K, Moseley L, Santillan M, Price J, Buentipo K, Bludau V, Thomas T, Fay L, Melton C, Kingsbery J, Benezue R, Simhan H, Bickus M, Fischer D, Kamon T, DeAngelis D, Mercer B, Milluzzi C, Dalton W, Dotson T, McDonald P, Brezine C, McGrail A, Latimer C, Guzzo L, Johnson F, Gerwig L, Fyffe S, Loux D, Frantz S, Cline D, Wylie S, Shubert P, Moss J, Salazar A, Acosta A, Hankins G, Hauff N, Palmer L, Lockhart P, Driscoll D, Wynn L, Sudz C, Dengate D, Girard C, Field S, Breault P, Smith F, Annunziata N, Allard D, Silva J, Gamage M, Hunt J, Tillinghast J, Corcoran N, Jimenez M, Ortiz F, Givens P, Rech B, Moran C, Hutchinson M, Spears Z, Carreno C, Heaps B, Zamora G, Seguin J, Rincon M, Snyder J, Farrar C, Lairson E, Bonino C, Smith W, Beach K, Van Dyke S, Butcher S, Thom E, Zhao Y, McGee P, Momirova V, Palugod R, Reamer B, Larsen M, Spong C, Tolivaisa S, VanDorsten J. Neonatal outcomes of elective early-term births after demonstrated fetal lung maturity. Am J Obstet Gynecol 2018; 219:296.e1-296.e8. [PMID: 29800541 DOI: 10.1016/j.ajog.2018.05.011] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2016] [Revised: 11/09/2016] [Accepted: 05/14/2018] [Indexed: 10/16/2022]
Abstract
BACKGROUND Studies of early-term birth after demonstrated fetal lung maturity show that respiratory and other outcomes are worse with early-term birth (370-386 weeks) even after demonstrated fetal lung maturity when compared with full-term birth (390-406 weeks). However, these studies included medically indicated births and are therefore potentially limited by confounding by the indication for delivery. Thus, the increase in adverse outcomes might be due to the indication for early-term birth rather than the early-term birth itself. OBJECTIVE We examined the prevalence and risks of adverse neonatal outcomes associated with early-term birth after confirmed fetal lung maturity as compared with full-term birth in the absence of indications for early delivery. STUDY DESIGN This is a secondary analysis of an observational study of births to 115,502 women in 25 hospitals in the United States from 2008 through 2011. Singleton nonanomalous births at 37-40 weeks with no identifiable indication for delivery were included; early-term births after positive fetal lung maturity testing were compared with full-term births. The primary outcome was a composite of death, ventilator for ≥2 days, continuous positive airway pressure, proven sepsis, pneumonia or meningitis, treated hypoglycemia, hyperbilirubinemia (phototherapy), and 5-minute Apgar <7. Logistic regression and propensity score matching (both 1:1 and 1:2) were used. RESULTS In all, 48,137 births met inclusion criteria; the prevalence of fetal lung maturity testing in the absence of medical or obstetric indications for early delivery was 0.52% (n = 249). There were 180 (0.37%) early-term births after confirmed pulmonary maturity and 47,957 full-term births. Women in the former group were more likely to be non-Hispanic white, smoke, have received antenatal steroids, have induction, and have a cesarean. Risks of the composite (16.1% vs 5.4%; adjusted odds ratio, 3.2; 95% confidence interval, 2.1-4.8 from logistic regression) were more frequent with elective early-term birth. Propensity scores matching confirmed the increased primary composite in elective early-term births: adjusted odds ratios, 4.3 (95% confidence interval, 1.8-10.5) for 1:1 and 3.5 (95% confidence interval, 1.8-6.5) for 1:2 matching. Among components of the primary outcome, CPAP use and hyperbilirubinemia requiring phototherapy were significantly increased. Transient tachypnea of the newborn, neonatal intensive care unit admission, and prolonged neonatal intensive care unit stay (>2 days) were also increased with early-term birth. CONCLUSION Even with confirmed pulmonary maturity, early-term birth in the absence of medical or obstetric indications is associated with worse neonatal respiratory and hepatic outcomes compared with full-term birth, suggesting relative immaturity of these organ systems in early-term births.
Collapse
|
42
|
Becquart O, Girard C, Lesage C, Guillot B. Angiosarcomes cutanés de la tête et du cou inopérables traités par bevacizumab et paclitaxel. Ann Dermatol Venereol 2018; 145:451-453. [DOI: 10.1016/j.annder.2018.02.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2017] [Revised: 11/04/2017] [Accepted: 02/13/2018] [Indexed: 10/17/2022]
|
43
|
Loget J, Saint-Martin C, Guillem P, Kanagaratnam L, Becherel PA, Nassif A, Fougerousse AC, Siham M, Girard C, Barthelemy H, Chaby G, Gabison G, Perrot JL, Pallure V, Beneton N, Boye T, Jacobzone C, Begon E, Bernard P, Reguiai Z. [Misdiagnosis of hidradenitis suppurativa continues to be a major issue. The R-ENS Verneuil study]. Ann Dermatol Venereol 2018; 145:331-338. [PMID: 29704958 DOI: 10.1016/j.annder.2018.01.043] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2017] [Revised: 11/20/2017] [Accepted: 01/19/2018] [Indexed: 11/25/2022]
Abstract
OBJECTIVE To provide physicians with an understanding of the factors behind significant delays in the diagnosis of hidradenitis suppurativa (HS) in France. PATIENTS AND METHODS This prospective multicentre national study conducted from October 2015 to March 2016 included all patients consulting for HS. Patient data were collected by means of a standardized questionnaire. Univariate and multivariate analyses were conducted to collect factors associated with a significant time to diagnosis of at least 5.5years, defined as the period between the onset of initial clinical signs and the time of formal diagnosis. RESULTS The 16 participating centres enrolled 312 patients (62% women), of average age 35years. The average age at onset of HS was 22years. Before formal diagnosis by a dermatologist (64% of cases), 170 (54%), 114 (37%) and 45 (15%) patients had previously consulted at least 3, 5 and 10 general physicians, respectively. The average time between the initial clinical signs of HS, the first dermatology visit and the definitive diagnosis was 6.2 and 8.4 years, respectively. Active smoking (OR adjusted 1.85; P=0.027) and disease onset at a younger age (adjusted OR 0.92; P<0.001) were both associated with significant delays in diagnosis. CONCLUSION These results emphasized misdiagnosis among HS patients but did not evidence any association between either sociodemographic or economic characteristics and the existence of significant times to diagnosis.
Collapse
Affiliation(s)
- J Loget
- Service de dermatologie, hôpital Robert-Debré, CHU de Reims, avenue du Général-Koenig, 51092 Reims cedex, France; ResoVerneuil, France.
| | - C Saint-Martin
- Unité d'aide méthodologique, hôpital Robert-Debré, CHU de Reims, avenue du Général-Koenig, 51092 Reims cedex, France
| | - P Guillem
- ResoVerneuil, France; Service de chirurgie adulte, clinique du Val-d'Ouest, 39, chemin de la Vernique, 69130 Ecully, France
| | - L Kanagaratnam
- Unité d'aide méthodologique, hôpital Robert-Debré, CHU de Reims, avenue du Général-Koenig, 51092 Reims cedex, France
| | - P-A Becherel
- ResoVerneuil, France; Service de dermatologie, hôpital privé d'Antony, Ramsay générale de santé, 27, avenue de la Providence, 92160 Antony, France
| | - A Nassif
- ResoVerneuil, France; Service de dermatologie, institut Pasteur, 25-28, rue du Dr-Roux, 75015 Paris, France
| | - A-C Fougerousse
- ResoVerneuil, France; Service de dermatologie, hôpital d'instruction des armées Bégin, 69, avenue de Paris, 94160 Saint-Mandé, France
| | - M Siham
- ResoVerneuil, France; Service de dermatologie, hôpital Avicenne, Assistance publique-Hôpitaux de Paris, 125, rue de Stalingrad, 93000 Bobigny, France
| | - C Girard
- ResoVerneuil, France; Service de dermatologie, centre hospitalier universitaire de Montpellier, 191, avenue du Doyen-Gaston-Giraud, 34295 Montpellier cedex, France
| | - H Barthelemy
- ResoVerneuil, France; Cabinet libéral de dermatologie, 2, rue Soufflot, 89000 Auxerre, France
| | - G Chaby
- ResoVerneuil, France; Service de dermatologie, centre hospitalier universitaire Amiens-Picardie site Nord, place Victor-Pauchet, 80054 Amiens cedex 1, France
| | - G Gabison
- ResoVerneuil, France; Cabinet libéral de dermatologie, 32, avenue du Maréchal-de-Lattre-de-Tassigny, 94410 Saint-Maurice, France
| | - J-L Perrot
- ResoVerneuil, France; Service de dermatologie, hôpital Nord, centre hospitalier universitaire de Saint-Étienne, 42055 Saint-Étienne cedex 2, France
| | - V Pallure
- ResoVerneuil, France; Service de dermatologie, centre hospitalier de Perpignan, 20, avenue du Languedoc, 66000 Perpignan, France
| | - N Beneton
- ResoVerneuil, France; Service de dermatologie, centre hospitalier du Mans, 194, avenue Rubillard, 72037 Le Mans, France
| | - T Boye
- ResoVerneuil, France; Service de dermatologie, hôpital d'instruction des armées Sainte-Anne, 2, boulevard Sainte-Anne, 83000 Toulon, France
| | - C Jacobzone
- ResoVerneuil, France; Service de dermatologie, centre hospitalier de Bretagne Sud, 5, avenue de Choiseul, 56322 Lorient cedex, France
| | - E Begon
- ResoVerneuil, France; Service de dermatologie, hôpital René-Dubos, 6, avenue de l'Île-de-France, 95300 Pontoise, France
| | - P Bernard
- Service de dermatologie, hôpital Robert-Debré, CHU de Reims, avenue du Général-Koenig, 51092 Reims cedex, France
| | - Z Reguiai
- ResoVerneuil, France; Service de dermatologie, polyclinique Courlancy, 38 bis, rue de Courlancy, 51100 Reims, France
| | | |
Collapse
|
44
|
Best M, Jachiet M, Molinari N, Manna F, Girard C, Pallure V, Cosnes A, Lipsker D, Hubiche T, Schmutz JL, Le Corre Y, Cordel N, Dandurand M, Dereure O, Guillot B, Du-Thanh A, Bulai Livideanu C, Chasset F, Bouaziz JD, Francès C, Bengoufa D, Vincent T, Bessis D. Distinctive cutaneous and systemic features associated with specific antimyositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients. J Eur Acad Dermatol Venereol 2018; 32:1164-1172. [PMID: 29237090 DOI: 10.1111/jdv.14759] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2017] [Accepted: 11/29/2017] [Indexed: 12/12/2022]
Abstract
BACKGROUND Identification of myositis-specific autoantibodies (MSAs) for dermatomyositis (DM) could allow the characterization of an antibody-associated clinical phenotype. OBJECTIVE We sought to define the clinical phenotype of DM and the risk of cancer, interstitial lung disease (ILD) and calcinosis based on MSA. METHODS A 3.5-year multicentre prospective study of adult DM patients was conducted to determine the clinical phenotype associated with MSAs and the presence of cancer, ILD and calcinosis. RESULTS MSAs were detected in 47.1% of 117 included patients. Patients with antimelanoma differentiation-associated protein-5 antibodies (13.7%) had significantly more palmar violaceous macules/papules [odds ratio (OR) 9.9], mechanic's hands (OR 8), cutaneous necrosis (OR 3.2), articular involvement (OR 15.2) and a higher risk of ILD (OR 25.3). Patients with antitranscriptional intermediary factor-1 antibodies (11.1%), antinuclear matrix protein-2 antibodies (6.8%) and antiaminoacyl-transfer RNA synthetase (5.1%) had, respectively, significantly more poikiloderma (OR 5.9), calcinosis (OR 9.8) and articular involvement (OR 15.2). Cutaneous necrosis was the only clinical manifestation significantly associated with cancer (OR 3.1). CONCLUSION Recognition of the adult DM phenotype associated with MSAs would allow more accurate appraisal of the risk of cancer, ILD and calcinosis.
Collapse
Affiliation(s)
- M Best
- Department of Dermatology, Saint-Eloi Hospital and Montpellier University Hospital, Montpellier, France
| | - M Jachiet
- Department of Dermatology, AP-HP, University of Paris VII Sorbonne Paris City and Saint-Louis Hospital, Paris, France
| | - N Molinari
- Department of Statistics, Montpellier University Hospital, Montpellier, France.,IMAG, CNRS, University of Montpellier, Montpellier, France
| | - F Manna
- Department of Statistics, Montpellier University Hospital, Montpellier, France
| | - C Girard
- Department of Dermatology, Saint-Eloi Hospital and Montpellier University Hospital, Montpellier, France
| | - V Pallure
- Department of Internal Medicine and Dermatology, Perpignan Hospital, Perpignan, France
| | - A Cosnes
- Department of Dermatology, Henri-Mondor Hospital, Créteil, France
| | - D Lipsker
- Faculty of Medicine, University of Strasbourg and Dermatologic Clinic, Strasbourg University Hospital, Strasbourg, France
| | - T Hubiche
- Department of Dermatology and Infectious Diseases, Fréjus Hospital, Fréjus, France
| | - J-L Schmutz
- Department of Dermatology, Brabois Hospital, Nancy University Hospital, Nancy, France
| | - Y Le Corre
- Department of Dermatology, Angers University Hospital, Angers, France
| | - N Cordel
- Unit of Dermatology and Internal Medicine, Guadeloupe University Hospital, Pointe-à-Pitre, Guadeloupe, France
| | - M Dandurand
- Department of Dermatology, Caremeau Hospital, Nîmes, France
| | - O Dereure
- Department of Dermatology, Saint-Eloi Hospital and Montpellier University Hospital, Montpellier, France.,Institut National de la Santé et de la Recherche Médicale (INSERM) U1058, Montpellier, France
| | - B Guillot
- Department of Dermatology, Saint-Eloi Hospital and Montpellier University Hospital, Montpellier, France.,Institut National de la Santé et de la Recherche Médicale (INSERM) U1058, Montpellier, France
| | - A Du-Thanh
- Department of Dermatology, Saint-Eloi Hospital and Montpellier University Hospital, Montpellier, France.,Institut National de la Santé et de la Recherche Médicale (INSERM) U1058, Montpellier, France
| | - C Bulai Livideanu
- Department of Dermatology, Toulouse University Hospital, Toulouse, France
| | - F Chasset
- AP-HP, Department of Dermatology and Allergology, Faculty of Medicine, Tenon Hospital, Sorbonne University, Paris, France
| | - J-D Bouaziz
- Department of Dermatology, AP-HP, University of Paris VII Sorbonne Paris City and Saint-Louis Hospital, Paris, France
| | - C Francès
- AP-HP, Department of Dermatology and Allergology, Faculty of Medicine, Tenon Hospital, Sorbonne University, Paris, France
| | - D Bengoufa
- Department of Immunology, Saint-Louis Hospital, Paris, France
| | - T Vincent
- Department of Immunology, Saint Eloi Hospital, and Montpellier University, Montpellier, France
| | - D Bessis
- Department of Dermatology, Saint-Eloi Hospital and Montpellier University Hospital, Montpellier, France.,Institut National de la Santé et de la Recherche Médicale (INSERM) U1058, Montpellier, France
| | | |
Collapse
|
45
|
Bessis D, Malinge M, Girard C. Isolated and unilateral facial angiofibromas revealing a type 1 segmental postzygotic mosaicism of tuberous sclerosis complex with c.4949_4982del
TSC
2
mutation. Br J Dermatol 2018; 178:e53-e54. [DOI: 10.1111/bjd.15868] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Affiliation(s)
- D. Bessis
- Department of Dermatology Saint‐Eloi Hospital University Hospital of Montpellier Montpellier France
- University of Montpellier Montpellier France
- INSERM U1058 Montpellier France
| | - M.‐C. Malinge
- Department of Biochemistry‐Genetics Molecular Genetics Unit Angers France
| | - C. Girard
- Department of Dermatology Saint‐Eloi Hospital University Hospital of Montpellier Montpellier France
- University of Montpellier Montpellier France
- INSERM U1058 Montpellier France
| |
Collapse
|
46
|
Michoux E, Dereure O, Guillot B, Girard C. Maladies infectieuses en dermatologie : valeur ajoutée d’une consultation de dermatologie à délai court. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
47
|
Barroil M, Bertrand AS, Girard C. Maladie chronique du greffon contre l’hôte (GVHD) cutanée localisée de répartition blaschkoïde. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
48
|
Schwob E, Bessis D, Lerisson M, Girard C. Carcinome verruqueux buccal plurifocal traité efficacement par erlotinib. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
49
|
Ariane M, Estève E, Fougerousse AC, Avenel-Audran M, Quiles-Tsimaratos N, Mery-Brossard L, Pauwels C, Le Guyadec T, Bastien M, Liégeon AL, Pallure V, Girard C, Alexandre M, Khatibi B, Poiraud C, Maccari F, Amy de la Breteque M, Sigal ML, Beauchet A, Mahé E. Utilisation de régimes d’éviction et médecines alternatives chez les patients atteints de psoriasis : une enquête nationale. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
50
|
Dubuc J, Girard C, Richard H, De Lasalle J, Laverty S. Equine meniscal degeneration is associated with medial femorotibial osteoarthritis. Equine Vet J 2017; 50:133-140. [PMID: 28667767 DOI: 10.1111/evj.12716] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2016] [Accepted: 06/23/2017] [Indexed: 11/28/2022]
Abstract
BACKGROUND There is limited information available concerning normal equine meniscal morphology, its degeneration and role in osteoarthritis (OA). OBJECTIVES To characterise normal equine meniscal morphology and lesions and to explore the relationship between equine meniscal degeneration and femorotibial OA. STUDY DESIGN Ex vivo cadaveric study. METHODS Menisci were harvested from 7 normal joints (n = 14 menisci) and 15 joints with OA (n = 30 menisci). A macroscopic femorotibial OA score (cartilage degeneration and osteophytosis) was employed to measure disease severity in each compartment. The femoral and tibial meniscal surfaces were scored for macroscopic fibrillation and tears (1-4). Histological sections (regions: cranial and caudal horn; body) were also scored for microscopic fibrillation and tears (0-3) and inner border degeneration (0-3). RESULTS Partial meniscal tears were present on both femoral and tibial surfaces in all 3 regions and most frequently identified on the femoral surface of the cranial horn of the medial meniscus and body of the lateral meniscus. There was a significantly positive correlation between the global medial meniscal macroscopic scores and osteophyte (r = 0.7, P = 0.002) or cartilage degeneration (r = 0.5, P = 0.03) scores within the medial femorotibial joint. The global medial meniscal macroscopic score was greater (P = 0.004) in the advanced OA joints compared with control joints. MAIN LIMITATIONS The menisci were principally from abattoir specimens without a known clinical history because of the challenge in obtaining a large number of specimens with a clinical diagnosis of femorotibial OA. CONCLUSIONS This study is the first to describe normal equine meniscal morphology and lesions. Meniscal lesions were identified in all segments and on both articular surfaces. Meniscal degeneration significantly correlated with OA severity in the equine medial femorotibial joint. The relationship between OA and meniscal pathology remains to be elucidated.
Collapse
Affiliation(s)
- J Dubuc
- Comparative Orthopedic Research Laboratory, Department of Clinical Sciences, Faculté de médecine vétérinaire, Université de Montréal, Saint-Hyacinthe, Quebec, Canada
| | - C Girard
- Comparative Orthopedic Research Laboratory, Department of Clinical Sciences, Faculté de médecine vétérinaire, Université de Montréal, Saint-Hyacinthe, Quebec, Canada
| | - H Richard
- Comparative Orthopedic Research Laboratory, Department of Clinical Sciences, Faculté de médecine vétérinaire, Université de Montréal, Saint-Hyacinthe, Quebec, Canada
| | - J De Lasalle
- Comparative Orthopedic Research Laboratory, Department of Clinical Sciences, Faculté de médecine vétérinaire, Université de Montréal, Saint-Hyacinthe, Quebec, Canada
| | - S Laverty
- Comparative Orthopedic Research Laboratory, Department of Clinical Sciences, Faculté de médecine vétérinaire, Université de Montréal, Saint-Hyacinthe, Quebec, Canada
| |
Collapse
|